Business context and reporting period
Canopy Growth Corporation’s comprehensive Form 10-K covers the fiscal year ended March 31, 2023, with comparison to fiscal 2022. Amounts are Canadian dollars unless noted. Although the request metadata says “2022 Q4,” this filing is an annual report; it also restates fiscal 2022 and the quarters ended June 30, September 30 and December 31, 2022.
The company sells cannabis and hemp products, vaporizers, sports nutrition products and skincare and wellness products. Its principal markets include Canada, the United States and Germany. It reported five segments for fiscal 2023: Canada cannabis, rest-of-world cannabis, Storz & Bickel, BioSteel and This Works.
Key financial metrics
Fiscal 2023 versus restated fiscal 2022; figures in millions of Canadian dollars except per-share data.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net revenue | $402.9 | $510.3 |
| Gross margin | $(104.1); (26%) | $(203.1); (40%) |
| Operating loss | $(2,848.3) | $(1,092.8) |
| Net loss | $(3,309.5) | $(330.6) |
| Basic and diluted loss per share | $(7.07) | $(0.79) |
| Adjusted EBITDA loss (non-GAAP) | $(349.7) | $(425.5) |
| Cash used in operating activities | $(557.5) | $(545.8) |
| Free cash flow (non-GAAP) | $(566.8) | $(582.5) |
At March 31, 2023, cash and cash equivalents were $677.0 million and short-term investments were $105.6 million. Current assets were $1,077.3 million and current liabilities were $803.8 million. Total debt was approximately $1.3 billion; the balance sheet classified $556.9 million of debt and convertible debentures as current. Separately, the filing identifies $468.0 million of cash-settled principal repayments due within 12 months. Operating cash flow was negative throughout the year.
Investing activities provided $433.4 million, largely reflecting redemptions of short-term investments; financing activities used $19.7 million. Cash and cash equivalents declined by $99.0 million during the year.
Material changes versus the prior comparable period
- Revenue fell 21%. Canada cannabis revenue declined 27% to $187.1 million, rest-of-world cannabis fell 51% to $38.9 million, Storz & Bickel declined 24% to $64.8 million, and This Works declined 19% to $26.0 million. BioSteel revenue rose 101% to $69.6 million, but its gross margin was negative $40.6 million, or (58%) of revenue.
- Canada cannabis gross margin remained deeply negative at (51%), although it improved from (83%) in fiscal 2022. The consolidated gross margin also improved, but remained negative.
- Adjusted EBITDA loss narrowed by $75.9 million, while net loss increased sharply. The net loss included $1.785 billion of goodwill impairment and substantial restructuring and other asset impairment charges; other expense was $466.0 million, compared with other income of $753.3 million in fiscal 2022.
- The company recorded $2.347 billion of total restructuring, asset impairment and related costs in fiscal 2023. These included $1.785 billion of goodwill impairments, $376.2 million of property, plant and equipment impairments, and $90.5 million of inventory write-downs and associated charges.
- The restatement reduced fiscal 2022 revenue by approximately $10.0 million, about 2% of reported revenue, and adjusted related receivables, other balances and segment disclosures. It also led to a $57.4 million BioSteel goodwill impairment in the September 2022 quarter. The filing states that the restated FY2022 annual adjustment did not change net cash used in operating activities.
Outlook, risks and unusual items
- Going concern and liquidity: Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. The company cited recurring losses, short-term debt obligations and dependence on additional financing. It warned that it may not meet the Credit Facility’s US$100 million minimum-liquidity covenant in the first quarter of fiscal 2025, potentially triggering acceleration of secured debt. Management plans include cost reductions, asset sales and seeking equity or debt financing, but success is not assured.
- Debt developments: The US$750 million secured term facility matures March 18, 2026. A discounted paydown reduced principal by approximately US$94.4 million in November 2022; a further approximately US$93.8 million reduction was completed in April 2023. The $337.4 million principal balance of 4.25% Canopy Notes was due July 2023 at year-end; after year-end, $100 million held by Greenstar was exchanged for a promissory note due December 31, 2024. The company also issued US$100 million of convertible debentures in February 2023; as of June 16, 2023, $7.1 million remained outstanding, with conversion and repayment in shares under the disclosed terms.
- Restructuring and strategy: Management is shifting to an asset-light model, consolidating Canadian cultivation, moving certain product formats to third-party sourcing or manufacturing, and reducing overhead. The company divested its Canadian retail stores and reported a workforce reduction of approximately 45% in Canada compared with March 2022. Management cautions that expected savings and benefits may not be achieved.
- Canopy USA: The planned U.S. cannabis strategy depends on shareholder, regulatory and other conditions, including approval of the Exchangeable Shares proposal and transaction milestones. Acreage, Wana and Jetty acquisitions were not completed as of the report; timing and outcomes remain uncertain. The May 2023 structural amendments mean Canopy Growth does not expect to consolidate Canopy USA, and the company’s future economic interest and third-party dilution are subject to transaction terms.
- Restatement and controls: BioSteel revenue recognition errors led to restatement of prior filings. Management found material weaknesses involving the control environment, BioSteel revenue and receivables controls, and IT general controls; disclosure controls and internal control over financial reporting were ineffective as of March 31, 2023. KPMG issued an adverse opinion on ICFR, while its opinion on the consolidated financial statements was unqualified. The company is subject to an SEC investigation and an informal Canadian securities-regulator inquiry, and faces shareholder class actions; outcomes and potential losses are not estimable from the filing.
- Other risks: Competition and cannabis price compression, inventory obsolescence, regulation and licensing, U.S. federal cannabis-law uncertainty, refinancing needs, further impairments, and volatility in the fair value of investments and warrants may affect results. No quantified company-wide revenue or profitability guidance is provided.
Most important facts for investors to verify
- Review the restated financial statements and BioSteel revenue corrections, and rely on this filing rather than the superseded prior reports.
- Track cash burn, debt maturities, financing progress and compliance with the US$100 million minimum-liquidity covenant.
- Assess whether the asset-light restructuring improves recurring gross margins and cash flow, particularly in Canada cannabis and BioSteel.
- Confirm remediation of the material weaknesses and monitor SEC, Canadian-regulator and shareholder-litigation developments.
- Verify the status, approvals, financing, dilution and eventual economic ownership implications of Canopy USA and the Acreage, Wana and Jetty arrangements.